908 Devices Inc. (MASS) vs Puma Biotechnology, Inc. (PBYI)
A side-by-side comparison of 908 Devices Inc. and Puma Biotechnology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MASS
908 Devices Inc.
$12.39HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
PBYI
Puma Biotechnology, Inc.
$9.56HealthcareDelayed quote: Oct 6, 2026, 12:24 PM EDT
Total return — MASS vs PBYI
growth of $100 · dividends reinvested · last 6yMASS -73.9% (-20.0%/yr)PBYI -10.0% (-1.7%/yr)PBYI compounded faster over this window
MASS PBYI
MASS vs PBYI: by the numbers
- •MASS is the larger company ($508M vs $487M market cap).
- •PBYI is profitable (11.55% net margin) while MASS runs a net loss (-56.68%).
- •MASS grew revenue faster over the past five years (18.92% vs 0.29% CAGR).
Metrics side by side
Valuation
| Metric | MASS | PBYI |
|---|---|---|
| P/E ratio | N/A | 18.52 |
| Forward P/E | N/A | 25.16 |
| P/S ratio | 8.36 | 2.10 |
| P/B ratio | 4.01 | 3.51 |
| EV / EBITDA | N/A | 10.48 |
| FCF yield | 0.09% | 8.44% |
Profitability
| Metric | MASS | PBYI |
|---|---|---|
| Gross margin | 49.79% | 74.83% |
| Operating margin | -46.01% | 13.16% |
| Net margin | -56.68% | 11.55% |
| ROE | -27.20% | 19.28% |
| ROIC | -18.90% | 18.26% |
Growth (annualized)
| Metric | MASS | PBYI |
|---|---|---|
| Revenue CAGR (5Y) | 18.92% | 0.29% |
| FCF CAGR (5Y) | N/A | 90.51% |
| Total return CAGR (5Y) | -17.66% | 9.26% |
Frequently asked
- Which has grown faster, MASS or PBYI?
- Over the past five years, MASS grew revenue faster — MASS at a 18.92% CAGR versus PBYI at 0.29%.
- Is MASS or PBYI more profitable?
- PBYI runs the higher net margin — MASS at -56.68% versus PBYI at 11.55%.
- How have MASS and PBYI total returns compared?
- Over the past 5 years, MASS delivered -17.66% and PBYI delivered 9.26% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Puma Biotechnology P/E ratio908 Devices ROEPuma Biotechnology ROE908 Devices operating marginPuma Biotechnology operating margin908 Devices revenue growthPuma Biotechnology revenue growth908 Devices free cash flowPuma Biotechnology free cash flow
908 Devices & Puma Biotechnology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.